维生素D与ω-3脂肪酸补充对2型糖尿病患者肾功能的影响:一项随机临床试验
该研究为2×2析因设计的随机临床试验,纳入1312例2型糖尿病成人,随机接受维生素D3(2000 IU/d)和ω-3脂肪酸(1 g/d)、维生素D3加安慰剂、安慰剂加ω-3脂肪酸或双安慰剂,随访5年。主要终点为基线至第5年基于血清肌酐和胱抑素C估计的肾小球滤过率(eGFR)变化。结果显示,维生素D3组与安慰剂组eGFR平均变化分别为-12.3 vs -13.1 mL/min/1.73 m2(差异0.9,95%CI -0.7至2.5),ω-3脂肪酸组与安慰剂组分别为-12.2 vs -13.1 mL/min/1.73 m2(差异0.9,95%CI -0.7至2.6),均无显著差异。结论认为 findings 不支持使用维生素D或ω-3脂肪酸补充来保护2型糖尿病患者的肾功能。
要点
- 在2型糖尿病成人中,维生素D3 2000 IU/d与安慰剂相比,5年eGFR平均变化差异为0.9 mL/min/1.73 m2(95%CI -0.7至2.5),无显著差异。
- ω-3脂肪酸1 g/d与安慰剂相比,5年eGFR平均变化差异为0.9 mL/min/1.73 m2(95%CI -0.7至2.6),无显著差异。
- 两种干预之间无显著交互作用。
- 肾结石发生于58例参与者(维生素D3组32例,安慰剂组26例),胃肠道出血发生于45例(ω-3脂肪酸组28例,安慰剂组17例)。
- 作者结论认为, findings 不支持使用维生素D或ω-3脂肪酸补充来保护2型糖尿病患者的肾功能。
适用人群与场景
- 2型糖尿病成人,平均年龄67.6岁,46%为女性,31%为种族或族裔少数群体。
- 2011年11月至2014年3月从美国全部50个州招募,作为VITAL试验的辅助研究。
处置流程与药物剂量
- 维生素D3 2000 IU/d口服,持续5年。
- ω-3脂肪酸(二十碳五烯酸和二十二碳六烯酸)1 g/d口服,持续5年。
研究设计与关键结果
- 随机临床试验,2×2析因设计,纳入1312例2型糖尿病成人,随访5年,934例(71%)完成研究。
- 基线平均eGFR为85.8(SD 22.1)mL/min/1.73 m2。
- 维生素D3组基线至第5年eGFR平均变化为-12.3(95%CI -13.4至-11.2)mL/min/1.73 m2,安慰剂组为-13.1(95%CI -14.2至-11.9)mL/min/1.73 m2,差异0.9(95%CI -0.7至2.5)mL/min/1.73 m2。
- ω-3脂肪酸组eGFR平均变化为-12.2(95%CI -13.3至-11.1)mL/min/1.73 m2,安慰剂组为-13.1(95%CI -14.2至-12.0)mL/min/1.73 m2,差异0.9(95%CI -0.7至2.6)mL/min/1.73 m2。
- 两种干预之间无显著交互作用。
- 肾结石发生于58例参与者(维生素D3组32例,安慰剂组26例);胃肠道出血发生于45例(ω-3脂肪酸组28例,安慰剂组17例)。
证据类型、等级与局限
- 证据类型:随机临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为, findings 不支持使用维生素D或ω-3脂肪酸补充来保护2型糖尿病患者的肾功能。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Chronic kidney disease (CKD) is a common complication of type 2 diabetes that can lead to end-stage kidney disease and is associated with high cardiovascular risk. Few treatments are available to prevent CKD in type 2 diabetes.
OBJECTIVE: To test whether supplementation with vitamin D3 or omega-3 fatty acids prevents development or progression of CKD in type 2 diabetes.
DESIGN, SETTING, AND PARTICIPANTS: Randomized clinical trial with a 2 × 2 factorial design conducted among 1312 adults with type 2 diabetes recruited between November 2011 and March 2014 from all 50 US states as an ancillary study to the Vitamin D and Omega-3 Trial (VITAL), coordinated by a single center in Massachusetts. Follow-up was completed in December 2017.
INTERVENTIONS: Participants were randomized to receive vitamin D3 (2000 IU/d) and omega-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid; 1 g/d) (n = 370), vitamin D3 and placebo (n = 333), placebo and omega-3 fatty acids (n = 289), or 2 placebos (n = 320) for 5 years.
MAIN OUTCOMES AND MEASURES: The primary outcome was change in glomerular filtration rate estimated from serum creatinine and cystatin C (eGFR) from baseline to year 5.
RESULTS: Among 1312 participants randomized (mean age, 67.6 years; 46% women; 31% of racial or ethnic minority), 934 (71%) completed the study. Baseline mean eGFR was 85.8 (SD, 22.1) mL/min/1.73 m2. Mean change in eGFR from baseline to year 5 was -12.3 (95% CI, -13.4 to -11.2) mL/min/1.73 m2 with vitamin D3 vs -13.1 (95% CI, -14.2 to -11.9) mL/min/1.73 m2 with placebo (difference, 0.9 [95% CI, -0.7 to 2.5] mL/min/1.73 m2). Mean change in eGFR was -12.2 (95% CI, -13.3 to -11.1) mL/min/1.73 m2 with omega-3 fatty acids vs -13.1 (95% CI, -14.2 to -12.0) mL/min/1.73 m2 with placebo (difference, 0.9 [95% CI, -0.7 to 2.6] mL/min/1.73 m2). There was no significant interaction between the 2 interventions. Kidney stones occurred among 58 participants (n = 32 receiving vitamin D3 and n = 26 receiving placebo) and gastrointestinal bleeding among 45 (n = 28 receiving omega-3 fatty acids and n = 17 receiving placebo).
CONCLUSIONS AND RELEVANCE: Among adults with type 2 diabetes, supplementation with vitamin D3 or omega-3 fatty acids, compared with placebo, resulted in no significant difference in change in eGFR at 5 years. The findings do not support the use of vitamin D or omega-3 fatty acid supplementation for preserving kidney function in patients with type 2 diabetes.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01684722.
参考来源
- de Boer IH, Zelnick LR, Ruzinski J, et al. Effect of Vitamin D and Omega-3 Fatty Acid Supplementation on Kidney Function in Patients With Type 2 Diabetes: A Randomized Clinical Trial. JAMA. 2019. PMID: 31703120. doi:10.1001/jama.2019.17380
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。